Welcome to our dedicated page for Avalo Therapeutics news (Ticker: AVTX), a resource for investors and traders seeking the latest updates and insights on Avalo Therapeutics stock.
Avalo Therapeutics, Inc. (NASDAQ: AVTX) is a clinical stage biotechnology company that regularly issues news and updates related to its focus on IL-1β-based treatments for immune-mediated inflammatory diseases. Company press releases consistently highlight progress with its lead asset, AVTX-009, a humanized monoclonal antibody targeting interleukin-1β (IL-1β), and its development in hidradenitis suppurativa (HS).
On this news page, readers can follow Avalo’s clinical development milestones, such as the design and execution of the Phase 2 LOTUS trial in adults with moderate to severe HS, completion of trial enrollment, and plans for future data readouts. The company’s releases describe the LOTUS trial as a randomized, double-blind, placebo-controlled Phase 2 study evaluating two AVTX-009 dosing regimens versus placebo, with HiSCR75 at Week 16 as the primary endpoint and several secondary HS disease activity and pain measures.
Avalo’s news flow also includes corporate and governance updates, including appointments of new board members and senior executives with backgrounds in clinical development, regulatory strategy, business development, finance and human resources. These announcements often describe related equity inducement grants and compensation arrangements, reflecting how the company structures incentives around its development priorities.
Investors and followers of AVTX can also find financial and capital markets communications in the company’s news, such as quarterly financial results summaries, cash runway commentary, and notices of participation in healthcare and biotechnology investor conferences. These items are frequently cross-referenced in Avalo’s Form 8-K filings, providing an official record of material events.
By reviewing Avalo Therapeutics news, readers gain insight into how the company is advancing AVTX-009 in hidradenitis suppurativa, how it frames the scientific rationale for IL-1β inhibition in immune-mediated inflammatory diseases, and how it is building its leadership and capital markets presence around this development strategy.
Avalo Therapeutics announced the appointment of Stephen Smolinski as Chief Commercial Officer effective January 3, 2022. He brings over 25 years of experience in commercial strategy development, having previously held senior roles at various biotechnology firms. Smolinski aims to enhance Avalo’s commercial capabilities and business development activities, particularly for the AVTX-002 therapy. As part of the hiring, he received a stock option for 400,000 shares of common stock, vesting over four years. This strategy is aligned with Avalo's focus on targeted therapeutics.
Avalo Therapeutics (AVTX) reported a positive update on its clinical programs, emphasizing the success of AVTX-002 in treating Crohn’s disease, where 50% of participants showed mucosal healing. The company plans to expand AVTX-002 for non-eosinophilic asthma, with Phase 2 trial results expected in late 2022. Additionally, while AVTX-007 was safe in multiple myeloma trials, it showed no efficacy and will focus on Adult Onset Still’s Disease moving forward. Avalo's rare disease programs are also progressing, with multiple trials scheduled for 2022.
Avalo Therapeutics (Nasdaq: AVTX) will hold a virtual Investor Day on January 6, 2022, from 8:00 a.m. to 10:00 a.m. ET. The event will feature presentations from key executives including CEO Michael Cola and CMO H. Jeffrey Wilkins, providing updates on their clinical pipeline. Key discussion points will include:
- Phase 1b study of AVTX-002 for Crohn’s disease, and plans for ulcerative colitis.
- Development updates for AVTX-007 targeting multiple myeloma.
- Progress on AVTX-803 for leukocyte adhesion deficiency type II.
- Overview of other pipeline programs and 2022 goals.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) has appointed Dr. June Almenoff and Mitchell Chan as independent board members, effective November 10 and December 1, 2021, respectively. They replace Dr. Suzanne Bruhn and Philip Gutry. Dr. Almenoff brings nearly 25 years of biopharma leadership experience, while Mr. Chan has over 15 years of finance expertise in life sciences. CEO Mike Cola expressed confidence that their combined experience will support the company's strategic priorities for the upcoming year.
Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage precision medicine company, announced that its senior management will present at two key healthcare conferences. The Stifel 2021 Virtual Healthcare Conference is set for November 17, 2021, at 4:00 PM ET, while the Jefferies 2021 London Healthcare Conference will take place from November 16-18, 2021, with a pre-recorded presentation available on November 18, 2021, at 8:00 AM GMT. Webcasts can be accessed through the company’s website.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced its financial results for Q3 2021, reporting cash and cash equivalents of $71.5 million. Following a successful public offering raising $31.5 million, Avalo continues to focus on pipeline development, with key data readouts anticipated in the coming months for multiple programs, notably AVTX-002 for Crohn's disease, expected in Q4 2021. The company also completed significant financing to support its operations and expansion into new therapeutic areas, including immuno-oncology and rare genetic diseases.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced that its senior management team will present at the Jefferies Next Generation IBD Therapeutics Summit on October 19, 2021. A pre-recorded webcast of the presentation will be available starting at 8:00 AM ET on the same day, accessible via the Investor section of the company's website. Avalo focuses on developing targeted therapeutics for unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases, aiming to deliver impactful medical solutions.
Horizon Technology Finance Corporation (NASDAQ: HRZN) reported strong performance for Q3 2021, achieving a record $141 million in loan originations, with $99 million attributed to HRZN. The portfolio ended with a committed backlog of $123 million, reflecting robust demand for venture loans. During the quarter, HRZN received $50 million in loan prepayments, boosting fee and interest income. The company closed new loan commitments totaling $91 million, with a significant pipeline of opportunities, suggesting ongoing growth potential for shareholders.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced that its senior management will present in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference, scheduled for September 29, 2021, at 2:00 PM ET. This engaging session will provide insights into the company's precision medicine initiatives targeting unmet clinical needs in immunology and rare diseases. A live webcast will be available on the company's website under the 'News/Events' section.
Avalo Therapeutics (AVTX) has successfully closed its underwritten offering of common stock, selling a total of 14,308,878 shares at a public offering price of $2.20 each. This offering raised approximately $31.5 million in gross proceeds before expenses. The shares were sold under an effective registration statement with the SEC, and Jefferies and RBC Capital Markets acted as joint book-running managers for the offering. The funds will support Avalo's commitment to developing targeted therapeutics for patients with unmet medical needs.
FAQ
What is the current stock price of Avalo Therapeutics (AVTX)?
What is the market cap of Avalo Therapeutics (AVTX)?
